Bukwang Pharmaceutical IND
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Bukwang Pharmaceutical IND is a South Korean pharmaceutical company that develops and supplies medicines for human health.
Its products reach patients and healthcare providers through the domestic and international pharmaceutical supply chain. The company is listed on KOSPI, Korea's main stock exchange.
Summary is AI-generated and may contain errors · figures from DART filings
Bukwang Pharmaceutical IND in five facts
What does Bukwang Pharmaceutical IND do?
Bukwang Pharmaceutical IND is a South Korean pharmaceutical company that develops and supplies medicines for human health.
Where is Bukwang Pharmaceutical IND listed and in which sector?
Bukwang Pharmaceutical IND (Korean name: 부광약품) trades under KRX code 003000 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Bukwang Pharmaceutical IND?
Its market capitalisation was US$289.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Bukwang Pharmaceutical IND's latest annual revenue and operating profit?
For fiscal year 2025, Bukwang Pharmaceutical IND reported revenue of US$151.5M, operating profit of US$10.7M and net income of US$9.4M, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was up 25.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meeting (notice)Oct 15
- DisclosureAug 31
- Operating results (consolidated) (preliminary) (fair disclosure)
Bukwang Pharmaceutical IND filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$38.5M (+33.8% year on year), operating profit of US$952K (−30% year on year) and net income of US$937K (−78.3% year on year).
Earnings · Jul 21 - [Amended] Decision to acquire shares/equity in another company
Bukwang Pharmaceutical IND updated the disclosed terms of an acquisition, now worth US$20.1M.
M&A · May 13 · 2 versions - Operating results (consolidated) (preliminary) (fair disclosure)
Bukwang Pharmaceutical IND filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$32.2M (−0.1% year on year), operating profit of US$759K (−62.6% year on year) and net income of US$794K (from a loss a year earlier).
Earnings · Apr 21 - [Amended] Supply contract signed
Bukwang Pharmaceutical IND updated a previously disclosed supply contract, now worth US$10.4M, about 10.47% of its recent annual revenue, running through Mar 2027.
Supply contract · Feb 27 - Cash/in-kind dividend decision
Bukwang Pharmaceutical IND declared a cash dividend of US$0.05 per share.
Dividend · Feb 23 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Bukwang Pharmaceutical IND reported consolidated results for FY2025: revenue of US$137M (+25.4% year on year), operating profit of US$9.68M (+775.2% year on year) and net income of US$8.6M (from a loss a year earlier).
Earnings · Feb 9